VX-659/TEZ/IVA
Sponsors
Vertex Pharmaceuticals Incorporated
Conditions
Cystic Fibrosis
Phase 3
A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy
TerminatedNCT03447262
Start: 2018-07-13End: 2020-09-09Updated: 2022-01-25
A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
CompletedNCT03447249
Start: 2018-03-07End: 2019-02-05Updated: 2020-03-13
A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)
CompletedNCT03460990
Start: 2018-05-01End: 2018-10-08Updated: 2019-10-17
Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age
TerminatedNCT03633526
Start: 2018-08-03End: 2019-01-18Updated: 2020-02-05